Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 5 (1) , 1-12
Abstract
Tuberculosis (TB) still is the principal cause of death from infectious disease and improved vaccination strategies are required to reduce the disease burden and break TB transmission. Here, we investigated different routes of administration of vectored subunit vaccines based on chimpanzee-derived adenovirus serotype-3 (ChAd3) for homologous prime-boosting and modified vaccinia virus Ankara (MVA) for heterologous boosting with both vaccine vectors expressing the same antigens from Mycobacterium tuberculosis (Ag85B, ESAT6, Rv2626, Rv1733, RpfD). Prime-boost strategies were evaluated for immunogenicity and protective efficacy in highly susceptible rhesus macaques. A fully parenteral administration regimen was compared to exclusive respiratory mucosal administration, while parenteral ChAd3-5Ag prime-boosting and mucosal MVA-5Ag boosting were applied as a push-and-pull strategy from the periphery to the lung. Immune analyses corroborated compartmentalized responses induced by parenteral versus mucosal vaccination. Despite eliciting TB-specific immune responses, none of the investigational regimes conferred a protective effect by standard readouts of TB compared to non-vaccinated controls, while lack of protection by BCG underpinned the stringency of this non-human primate test modality. Yet, TB manifestation after full parenteral vaccination was significantly less compared to exclusive mucosal vaccination.Keywords
This publication has 48 references indexed in Scilit:
- Influenza A Virus Impairs Control of Mycobacterium tuberculosis Coinfection Through a Type I Interferon Receptor–Dependent PathwayThe Journal of Infectious Diseases, 2013
- The Mycobacterium tuberculosis regulatory network and hypoxiaNature, 2013
- Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trialsExpert Review of Vaccines, 2013
- Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector ImmunizationThe Journal of Immunology, 2013
- Management of Multidrug Resistant TuberculosisSeminars in Respiratory and Critical Care Medicine, 2013
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesScience Translational Medicine, 2012
- Whole genome identification of Mycobacterium tuberculosisvaccine candidates by comprehensive data mining and bioinformatic analysesBMC Medical Genomics, 2008
- Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan AfricaEmerging Infectious Diseases, 2006
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Variation in protection by BCG: implications of and for heterologous immunityThe Lancet, 1995